Kornimate/medical-research-clean huggingface dataset:
a retrospective protocol empowering precision research in colorectal cancer (alfaomega-retrò)

Conditions: Colorectal Cancer

Summary: alfaomega-retrò will be exploited to retrospectively collect clinical and imaging data and archival samples to be used for validation and correlative studies on markers discovered by cutting-edge translational projects within the airc5x1000 program "insights into the evolving heterogeneity of colorectal cancer (crc): from mechanism to therapies" (an ongoing multi-institutional research program).

alfaomega-retrò, the retrospective "mirror" protocol of alfaomega (protocol n. ifom-cpo003/2018/po002), has been designed to build a retrospective collection of clinically annotated data and biological samples retrieved from colorectal cancer patients (crc). the repository will feed experimental precision research aimed at i) defining a new taxonomy of crc based on evolutionary patterns (retrospectively assessed on patient's samples), ii) developing and evaluating innovative biomarker-specific therapeutic strategies derived from or together with alfaomega. the following data and biological samples will be collected: * clinical data (demographics, medical history, cancer diagnosis \& history, treatment assessment,). * imaging data (ct-scans, mri, pet...). * formalin-fixed paraffin-embedded (ffpe) tissue (either from surgical resections or diagnostic biopsies). * frozen biological samples (blood, plasma, pbmc, stools, buccal swabs, urines, etc.).

Eligibility criteria:
inclusion criteria: * histologically-confirmed diagnosis of colorectal cancer (any stage). * age \>18 years at the time of diagnosis. * availability of clinically-annotated radio-imaging data and/or diagnostic formalin-fixed paraffin embedded (ffpe) blocks (surgical resections and/or tumor biopsies), or at least 10 slides (preferably 20). ffpe tissue blocks are always preferred to slides. * verification that the patient could not be reached for informed consent in accordance with applicable national regulations. exclusion criteria: * if inclusion criteria are not met

Keywords: colorectal cancer crc gastrointestinal disease
vitreous hyper reflective dots in association with pseudophakic cystoid macular edema

Conditions: Cystoid Macular Edema Following Cataract Surgery; Vitreous Hyperreflective Dots

Summary: the aim of this study is to assess the association between vitreous hyper-reflective dots (vhd) and the macular thickness changes following uneventful phacoemulsification. in this prospective study the investigators performed optical coherence tomography (oct) imaging in patients undergoing cataract surgery preoperatively and postoperatively after 1 week, 1 month and 3 months and analyzed the octs for vhds. the investigators then measured the macular thickness in patients with vhds and without vhds and correlated the macular thickness with the number of vhds.


Eligibility criteria:
inclusion criteria: * patients undergoing cataract surgery * minimum age 18 years * phacoemulsification technique * subsequent implantation of a monofocal hydrophobic acrylic intraocular lens exclusion criteria: * intraoperative complications including capsule rupture with or without anterior vitrectomy * iris bites * previous interventions including vitrectomy * glaucoma surgery * exudative or dry age-related macular degeneration * presence of diabetes * history or presence of retinal vein occlusion or uveitis * epiretinal glioses

Keywords: vhd phacoemulsification cme
herpes zoster vaccine for bone marrow transplant donors

Conditions: Herpes Zoster

Summary: the purpose of this study is to determine whether vaccination of stem cell donors with zostavax can reduce the rate of herpes zoster reactivations in transplant recipients. the clinical hypotheses is: 1) that zostavax given to stem cell donors will induce protective vzv specific t cell proliferation in allogeneic stem cell transplant recipients that can be transferred to recipients; 2) and that donor vaccination with zostavax is safe for transplant recipients as measured by viral load measurement by polymerase chain reaction assay (pcr) at the time of stem cell donation.

infection is a major cause of morbidity and death among haemopoietic stem cell transplantation patients (hscts). beyond the initial post-transplant (bmt) phase of neutropenia, the most common infections are cytomegalovirus (cmv) and fungal infections. another common infection for which bmt patients are at increased risk is varicella-zoster virus (vzv) (both primary varicella and herpes zoster). vzv infection is controlled by specific t cell responses that are impaired post stem cell transplant. heat inactivated vzv vaccine has been shown to more than halve the incidence of herpes zoster in adult bmt patients undergoing autologous transplantation. clinical protection was correlated with in vitro cd4 t-cell proliferation in response to varicella-zoster virus. being a live vaccine, attenuated vzv and (herpes zoster (hz) vaccines are contraindicated within 24 months after allogeneic hsct. however, priming of donor t-cells with herpes zoster vaccine may be a feasible alternative. one possible complication is the transfer of live virus from vaccinated donors to immunocompromised stem cell transplant recipients. normal donors donating for hla matched siblings will be vaccinated with the varivax vaccine prior to donation. stem cell products will be assessed at the time of donation for evidence of vzv by pcr and for response to vaccination by t cell proliferation. transfer of vzv proliferative responses in transplant recipients will be assessed by vzv specific t cell proliferation at 3, 6, 9 and 12 months post transplantation.

Eligibility criteria:
inclusion criteria: * allogeneic hsct recipient-donor pair * donor aged 50 years and over * recipients and donors willing to be recruited as a pair to this study * recipients undergoing myeloablative or non myeloablative non t cell depleted, allogeneic stem cell transplants from hla identical or 1 hla antigen mismatched siblings. exclusion criteria: * lack of informed consent * inability to recruit donor and recipient as a pair * autologous transplant * contraindication to zostavax in donor * donor aged \<50 years * recipient vzv immunoglobulin g (igg) negative pre-transplantation, * donor vzv igg negative * pregnancy of donor at randomisation * inability to follow study protocol (donor and recipient) * malignancy or immunosuppression of hsc donor * expected hsct within 30 to 42 days

Keywords: zostavax herpes zoster vzv vaccination allogeneic haemopoietic stem cell transplantation
manually controlled infusion vs target controlled infusion for strokethrombectomy

Conditions: Stroke, Ischemic; Stroke/Brain Attack; Anesthesia; Hemodynamic Instability

Summary: the goal of this randomized controlled trial is to compare manual general anesthesia induction to general anesthesia induction guided by target controlled infusion system in cerebral ischemic stroke the main questions it aims to answer are: * does target controlled infusion has a more favorauble hemodynamic profile than manual general anesthesia induction? * do patients receiving general anesthesia with target controlled infusion system have a more favourable outcome? participants will receive general anesthesia induction with a target controlled infusion system and will be compared to patients receiving manual general anesthesia induction.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * anterior cerebral circulation stroke * patient eligible for mechanical trombectomy * mrs ≤ 2; * fasting patients (\>6 h solid, \>2 hours liquids) * glashow coma scale more than seven. exclusion criteria * patient in general anesthesia at hospital arrival * associated hemorrhagic stroke
trends in intellectual development in down syndrome

Conditions: Down Syndrome

Summary: previous foreign studies revealed that the iq in down syndrome (ds) declines with age, but not any investigation of domestic data in taiwan was available. individuals with ds are characterized by limited verbal development, and in this article, authors look into the diverging verbal-nonverbal abilities in the ds phenotype.

the present study investigated this by analysis the test results of development /intelligence scales. to compare initial cross-sectional data with longitudinal follow-up, about 12 people with ds were included.

Eligibility criteria:
inclusion criteria: * down syndrome with psychological test results exclusion criteria: * comorbidity of severe autism or visual/auditory impairment

Keywords: down syndrome iq mental age neuropsychological function
the value of 68ga-fapi pet/ct for evaluating peritoneal treatment response

Conditions: Peritoneal Metastasis; FAPI

Summary: peritoneal metastases (pm), commonly originating from gastrointestinal and ovarian cancers, are associated with a poor prognosis and limited treatment options due to the diffuse nature of the disease and the inability of systemic chemotherapy to adequately penetrate the peritoneal surface. intraperitoneal (ip) chemotherapy has emerged as a potential treatment modality for patients with extensive pm, allowing for higher local drug concentrations while minimizing systemic toxicity. however, current response evaluation methods, such as ct scans, have low sensitivity for detecting pm, and second-look laparoscopy, although more accurate, is invasive and unsuitable for repeated assessments. the ⁶⁸ga-fapi pet/ct scan offers a promising non-invasive alternative for assessing peritoneal response to ip chemotherapy. this imaging technique targets the fibroblast activation protein, which is overexpressed in cancer-associated fibroblasts within the tumor microenvironment. early studies have shown that ⁶⁸ga-fapi pet/ct is a highly sensitive too in detecting peritoneal metastases. given these advantages, the investigators hypothesize that ⁶⁸ga-fapi pet/ct could improve the evaluation of treatment response in patients undergoing ip chemotherapy for pm, offering a non-invasive and accurate alternative to current methods. the primary objective of this study is to investigate the accuracy of ⁶⁸ga-fapi pet/ct for evaluating peritoneal response in patients with peritoneal metastases undergoing repeated ip chemotherapy.


Eligibility criteria:
inclusion criteria: * a planned start of repeated ip chemotherapy (with or without the combination of systemic chemotherapy) for macroscopic peritoneal metastases; * who-performance score of 0 to 1; * aged 18 years or older; * written informed consent according to the ich-gcp and national/local regulations. exclusion criteria: * impaired renal function, defined as egfr \<25 ml/min/1,73 m2. an exception can be made in consultation with the treating physician; * pregnancy/breastfeeding. for the latter, temporary discontinuation may be considered; * known allergic reaction to therapeutic radiopharmaceuticals; * inability to lie still on the back for the duration of pet-ct; * any (other) condition, disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may affect the interpretation of the results, or which might contribute substantially to the patient's experience of study burden (such as non-suppressible claustrophobia).

Keywords: peritoneal metastasis intraperitoneal fapi pet/ct
insulin resistance in idiopathic oligospermia and azoospermia

Conditions: Insulin Resistance; Oligospermia; Azoospermia

Summary: insulin resistance in men can be the underlying major factor in reproductive abnormalities ( chronic hypospermatogenesis ) as well as metabolic abnormalities similar to polycystic ovarian syndrome ( pcos ) in women.

during the past decade ir has been recognized as a major contributor to the pathogenesis of chronic anovulation, hyperandrogenism and metabolic abnormalities associated with pcos . theoretically ir in men may result in a similar reproductive abnormalities ( chronic hypospermatogenesis ) as well as other metabolic abnormalities similar to what happens in pcos in women .

Eligibility criteria:
inclusion criteria: * sperm count less than 10 million per milliliter * non-obstructive azoospermia exclusion criteria: * high fsh ( \> 10 miu/ ml ) * high prolactin ( \> 36 miu/ml ) * abnormal karyotype * azf

Keywords: insulin resistance unexplained azoospermia unexplained oligospermia
observational program to assess respiratory syncytial virus (rsv) hospitalization rate in population of children at high-risk of serious rsv illness who received palivizumab immunoprophylaxis

Conditions: Respiratory Syncytial Virus (RSV)

Summary: this was a non-interventional, prospective, multi-center study with no control group designed to assess the effectiveness of palivizumab in a population of infants at high-risk of serious respiratory syncytial virus (rsv) illness (infants born ≤ 35 weeks of gestation and infants ≤24 months with bronchopulmonary dysplasia (bpd) or congenital heart disease (chd)). participants received immunoprophylaxis during the rsv season, defined as october 2014 through april 2015, in routine clinical settings throughout the russian federation.

participants received intramuscular injections of palivizumab according to physicians' prescription and the local label. the local label recommended 1 month injection intervals between 5 sequential injections at a dose of 15 mg/kg. participants could have received from 3 to 5 monthly injections of palivizumab during the 2014 - 2015 rsv season and the duration of this study.

Eligibility criteria:
inclusion criteria: * planned prescription of palivizumab for immunoprophylaxis during rsv season or participants for whom palivizumab was prescribed and who received the first dose of palivizumab no later than 60 days before enrollment in the study * infants at high risk of severe rsv infection defined as fulfilling at least one of the following: * infants born ≤35 weeks gestational age and are ≤6 months of age at the onset of the rsv season; * infants ≤24 months of age and with a diagnosis of bpd (defined as oxygen requirement at a corrected gestational age of 36 weeks); * infants ≤24 months of age with hemodynamically significant chd, unoperated or partially corrected. * written authorization to use individual data signed by parents or child representative exclusion criteria: * major congenital malformation aside from chd * chronic pulmonary disease other than bpd * acute period of any infection * contraindication to palivizumab prescription according to local label * administration of a product possibly containing rsv-neutralizing antibody within 30 days prior to enrollment or current administration (includes, but is not restricted to, the following: rsv hyperimmunoglobulin, polyclonal intravenous immunoglobulin, cytomegalovirus hyperimmunoglobulin, varicella zoster hyperimmunoglobulin)

Keywords: immunoprophylaxis palivizumab
depakote er in borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: this study examines the effect of depakote er versus placebo in a randomized trial of borderline personality disorder. patients all participate in dbt therapy and those who are not responsive are assigned to either depakote er or placebo for up to 12 weeks. borderline personality symtoms are measured and side-effects are assessed.


Eligibility criteria:
inclusion criteria:male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. must be in good physical health - exclusion criteria:major psychiatric illness on axis i - schizophrenia or bipolar disorder. may not have current mdd. may not be dependent on illicit substances or alcohol. -

Keywords: borderline personality disorder
the role of augmented fixation techniques in fragility fracture pelvis (ffp)

Conditions: Fragility Fracture

Summary: assessment of the role of augmented fixation of fragility fracture pelvis in improving functional outcome as a primary outcome and improving union and decreasing mortality and complications as secondary outcomes at 6 months and one year follow up.

during the process of aging, the quality of bones deteriorates making bones more vulnerable for fractures after minor trauma or from normal daily activities. this poor bone quality together with comorbidities increase healing problems and complications and make fixation more difficult. moreover, immobilization due to fractures has serious complications especially in the elderly. for all theses, fragility fracture-which is defined by who as a fracture that is caused by an injury that would be insufficient to fracture normal bones and is the result of reduced compressive and or torsional strength of bone - these fractures have unique criteria making them a special category with its own concerns. one of these fractures is fragility fracture pelvis (ffp) which is expected to triple between 2005 and 2030. this type of fracture has its huge effect on morbidity and mortality of this vulnerable group of people. due to its special criteria , a new classification system was developed to classify it known as rommens classification system. this was followed by many literatures focused on this fracture, its morbidity and mortality, role of surgery, minimal invasive techniques and different augmentation fixation techniques, but they did not reach to a clear algorithm for management and did not clearly identify the role of augmented fixation techniques on different outcomes of this fracture . fixation augmentation techniques which are defined as surgical techniques aimed at increasing implant stability and used in poor bone quality like in geriatric population. the investigators hypothesis is augmented fixation will improve the functional outcomes of fragility fracture pelvis. these techniques may include percutaneous transsarcal screws fixation, tension band plating, infix technique, triangular fixation and cement augmentation techniques. the investigators will try to answer this question which is "what is the effect of augmented fixation techniques on functional outcomes of fragility fracture pelvis? ''.

Eligibility criteria:
inclusion criteria: 1. patients above age of sixty years. 2. fragility fracture pelvis 3. injury severity score below 17. 4. controlled comorbidities exclusion criteria: 1. malignancy in bony pelvis. 2. chronic kidney disease on regular dialysis, 3. skin lesion at admission like morel-lavallée lesion.
safety and effectiveness of an investigational agent (gm-611) in patients with diabetic gastroparesis

Conditions: Gastroparesis

Summary: this study is intended to evaluate the potential to relieve the symptoms associated with gastroparesis during 12 weeks of treatment with oral tablets given twice a day of gm-611 5mg, 10mg or placebo to type i or ii diabetics who require insulin. additionally the study will evaluate the safety and tolerability of gm-611 compared to placebo, the levels of gm-611 in the blood, and the possible effect of gm-611 on diabetic control.


Eligibility criteria:
inclusion criteria: major inclusion criteria - others stipulated within the protocol the study physician must assure you have/are: * must be at least 18 years of age and have diabetes mellitus requiring insulin, which may be in addition to oral anti-diabetic agents. * at least a three month history of the symptoms of gastroparesis that may include: early satiety (feeling full soon after beginning a meal), persistent fullness (long after eating), abdominal distention or bloating, nausea and vomiting. - no evidence of mechanical gastric obstruction, or other gastric problems since the onset of gastroparesis symptoms. * you may be required to under go a gastric emptying test (get) procedure. * you must be willing and able to maintain a daily telephone diary and consent to participate in this study. exclusion criteria: major exclusion criteria - others stipulated within the protocol the study physician must assure you do not have/are not: * prior history of gastric surgery, excluding reflux surgery. * inability to withdraw from current prokinetic agents (e.g., metoclopramide, erythromycin, others) prior to, and during the study. * unstable current medical or surgical condition, or a recent history of frequent hospitalizations. * a history of: hiv, recurring infection affecting the gastrointestinal track, cirrhosis, acute or chronic liver disease, active pancreatitis, cholecystitis, psychosis, severe depression, parkinson's disease, myopathy, scleroderma, eating disorder, or organ transplant. * evidence or history of qt-prolongation, or use of drugs that are, or may be associated with qt-prolongation are prohibited. * may not be pregnant, breast-feeding or not using approved methods of contraception. * an allergy or intolerance to macrolide antibiotics (e.g., erythromycin). * use of any investigational drug within 30 days prior to screening.

Keywords: gm-611 diabetic gastroparesis bloating delayed gastric emptying mitemcinal
combination iron chelation therapy

Conditions: Iron Overload; Thalassemia

Summary: patients with beta-thalassemia (cooley's anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy. compliance with the use of the only fda-approved drug for removing excess iron from patients (desferal) continues to be a major problem despite convincing evidence that it markedly reduces morbidity and prolongs life. the full potential of iron-chelation therapy will not be realized until an orally-effective drug is available. this small trial is testing the premise that a combination of drugs as a new approach to iron chelation therapy may reduce side effects and increase efficacy. if both drugs can be given orally, there may be a better chance of finding a suitable alternative to desferal. several combinations of experimental iron chelating drugs are being used in this trial.


Eligibility criteria:
inclusion criteria: * iron overload exclusion criteria: * overt cardiac disease

Keywords: chelation therapy combination chemotherapy iron poisoning thalassemia chelating agent deferoxamine drug screening /evaluation therapy evaluation
emergency medical services and epilepsy in switzerland

Conditions: Epilepsy

Summary: retrospective data analysis, all emergency medical services of the city of zurich interventions due to epileptic convulsions during june 2013 and december 2014 have been analyzed regarding the type of drug used, its application mode and the application mode based success. furthermore, children versus adults were compared. continuous variables were summarized as mean ± standard deviation (sd) and also presented as median \[minimum; maximum\]. groups were compared using the independent samples t-test. p-values \< 0.05 are considered significant.


Eligibility criteria:
inclusion criteria: * emergency calls for epileptic seizures received by the emergency medical system of zurich,switzerland, * the use of midazolam or diazepam or no drug used. exclusion criteria: * the use of any other first line drug to stop seizures than the two mentioned above e.g. thiopental

Keywords: epilepsy emergency medical services